Amgen (AMGN) announced that it has completed its acquisition of Horizon Therapeutics (HZNP) for $116.50 per share in cash, representing a transaction equity value of approximately $27.8B. Amgen expects to provide updated FY23 guidance during its third quarter earnings call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
- Mirati Therapeutics price target raised to $72 from $31 at BMO Capital
- Here’s Why Mirati Therapeutics Stock (NASDAQ:MRTX) Soared Yesterday
- FDA Oncologic Drugs Advisory Committee holds virtual meeting
- Horizon Therapeutics announces acquisition by Amgen approved in Ireland
